Overview
Jacob Donoghue, MD, PhD, is chief executive officer and co-founder of Beacon Biosignals, a company built on a shared mission to unlock the power of brain data to transform how neurological and psychiatric conditions are diagnosed, treated, and understood. Beacon’s about page states Donoghue leads the company’s efforts to transform diagnosis and treatment of neurological, psychiatric, and sleep disorders using AI-powered sleep EEG analytics.
Beacon combines advanced AI-driven technology with deep biopharma domain knowledge to accelerate neuroscience innovation, with collective expertise spanning neuroscience, machine learning, academic and pharmaceutical research, and product development.
Role and company
As CEO and Co-Founder, Donoghue leads Beacon alongside CTO and co-founder Jarrett Revels and a leadership team including Chief Clinical Officer Matt Alkaitis, MD, PhD, and Chief Business Officer David Matthews, PhD. Beacon serves life sciences partners and clinical sleep testing markets with AI analytics applied to electroencephalography data captured during sleep.
Beacon’s mission emphasizes accelerating innovation to get life-changing treatments to patients faster — positioning the company as neurotechnology infrastructure for pharma clinical development and sleep medicine operations.
Background and career context
Donoghue received his MD from Harvard Medical School and PhD in neuroscience from MIT, where his research focused on how neuroactive compounds modulate brain network activity per Beacon’s leadership biography. This dual clinician-scientist training shapes Beacon’s credibility with pharmaceutical partners evaluating digital biomarkers in CNS trials.
Co-founder Jarrett Revels’ MIT research on compiler techniques for machine learning frameworks complements Donoghue’s neuroscience focus — a technical pairing reflected in Beacon’s engineering-heavy leadership roster.
Company-building or leadership context
Beacon was built by a team of leading experts combining AI-driven technology with biopharma domain knowledge per its about page. The company reports a multidisciplinary workforce including PhDs and MDs across analytics, clinical strategy, regulatory affairs, and hardware engineering. Beacon is backed by leading investors who believe in transforming brain health through AI-powered neurotechnology.
Donoghue’s CEO role spans scientific credibility for pharma partnerships and operational scale for clinical sleep services — dual requirements uncommon in pure software AI startups.
Public milestones
Beacon’s about page documents leadership appointments across clinical, regulatory, and commercial functions reflecting scale beyond startup phase. The company markets home sleep testing products and life sciences analytics services on beacon.bio reviewed in 2026.
Donoghue is named CEO and Co-Founder on Beacon’s official leadership page — the primary source for his operating role in this profile.
Why their work matters
Beacon under Donoghue applies AI to sleep EEG — a data-rich modality historically underused in psychiatric and neurological drug development because analysis required specialized manual scoring. Digitizing and automating sleep EEG interpretation could compress clinical trial timelines for CNS therapies where sleep architecture serves as a pharmacodynamic endpoint.
For healthcare AI readers, Beacon represents neuro-AI distinct from radiology or documentation categories — but shares the need for FDA-cleared analytics and pharma-grade evidence generation.
Sources and references
Primary sourcing: Beacon Biosignals About leadership page, reviewed July 10, 2026.
- Beacon Biosignals — About (beacon.bio)
Education credentials sourced only from Beacon leadership biography. No funding amounts cited beyond investor logos on official page.
Beacon’s about page emphasizes scientific rigor powered by cutting-edge technology and built with patients in mind across its multidisciplinary team. Donoghue’s MD from Harvard Medical School and PhD in neuroscience from MIT — researching how neuroactive compounds modulate brain network activity — inform Beacon’s credibility with biopharma partners evaluating sleep EEG digital biomarkers in CNS development programs.
Beacon markets life sciences analytics and home sleep testing products on beacon.bio, extending Donoghue’s neuro-AI thesis from research collaborations into operational clinical sleep services — a dual revenue model uncommon in pure software neuroimaging startups.